Manufacturing Techniques of Orally Dissolving Films - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Manufacturing Techniques of Orally Dissolving Films
The manufacture of orally dissolving films is done by various methods such as solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling. The authors discuss these methods and the various parameters in which dissolving films are evaluated.


Pharmaceutical Technology
Volume 35, Issue 1, pp. 70-73

Clinical and regulatory requirement

To indicate bioequivalency of a product to that of existing oral drug, an abbreviated new drug application is required. In-vitro dissolution studies and therapeutic equivalence are considered. Comparative bioequivalence between an orally disintegrating tablet and an ODF can be evaluated. If the ODF exhibits a different target pharmacokinetic profile compared with the existing marketed product, the ODF is considered a new dosage form. For a new dosage form, a new clinical study is required. A new clinical study offers the advantage of three years of marketing exclusivity to the product. Preclinical toxicity studies are not required if the molecule is the same as that of the approved product. Safety, tolerability, and efficacy features are to be demonstrated in such trials. Oral mucosa-irritation testing is carried out in both animal models and humans. The hamster-cheek pouch is the most appropriate model for predicting irritation criteria before testing in humans (12).

Conclusion

ODFs are a possible alternative dosage form to orally disintegrating tablets. These films offer the benefits of pleasant mouthfeel and rapid disintegration in the mouth. Solvent casting, hot-melt extrusion, semisolid casting, solid-dispersion extrusion, and rolling are important manufacturing methods to produce these films.

Renuka Mishra* is an assistant professor, and Avani Amin is a professor in the Department of Pharmaceutics and Pharmaceutical Technology, the Institute of Pharmacy, Nirma University, Ahmedabad, Gujarat, India, Sarkhej-Gandhinagar Highway, Ahmedabad, Gujarat, India,

*To whom all correspondence should be addressed.

References

1. S. Borsadia, D. O'Halloran, and J.L. Osborne, Drug Del. Tech. 3 (3), 63–66 (2003).

2. T. Ghosh and W.Pfister, "Intraoral Delivery Systems: An Overview, Current Status and Future Trends," in Drug Delivery to the Oral Cavity: Molecules to Market, T. Ghosh and W. Pfister, Eds. (Taylor & Francis, Florida, CRC Press, 2005), pp. 1–34.

3. P. V. Arnum, "Outsourcing Solid Dosage Manufacturing," Pharm. Technol. 30 (6), 44–52 (2006).

4. R. Mishra and A. Amin, Pharm. Technol. Eur. 19 (10), 35–39 (2007).

5. M. Repka et al., "Hot Melt Extrusion," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J. Boylan, Eds. (Marcel Dekker Inc., New York, Vol. 2, 2nd Edition, 2002), pp. 1488–1504.

6. M.A. Repka and J.W. McGinity, Pharm. Dev. Technol. 6 (3), 297–304 (2001).

7. M. Repka and J.W. McGinity, J. Controlled Release 76 (3), 341–351 (2001).

8. J. Breitenbach, Eur. J. Pharm. Biopharm. 54 (2), 107–117 (2002).

9. A. Arya et al., Int. J. Chem. Tech. Research 2 (1), 578–583 (2010).

10. Gole et al., "Pharmaceutical and Other Dosage Forms," US Patent 5648093, Jul. 1997.

11. R.K. Yang et al., "Thin Film with Non-Self Aggregating Uniform Heterogeneity and Drug Delivery Systems Made Therefrom," US Patent Application 20080226695.

12. R. Mishra and A. Amin, Pharm. Technol. 33 (2), 48–56 (2009).

13. R.P. Dixit, S.P. Puthli, J. Controlled Release 139 (2), 94–107 (2009).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here